Results about: tumor mutations

Inter- and intra-cellular communication is fundamental for the survival of multi-cellular organisms, and defects in this process are often key features of many diseases. At the molecular level, the basis for information transfer is the formation of complex networks of interacting components.

Errors made by 'DNA spellchecker’ revealed as important cause of cancer

Fran Supek (IRB Barcelona) and Ben Lehner (CRG) identify important processes that create mutations that cause cancer by studying the genomes of more than 1,000 tumors.

Many mutations in human cancers are caused by mistakes made by a repair mechanism or ‘DNA spellchecker’ rather than the actual damage to DNA caused by the environment.

Sunlight and alcohol consumption increase the rate at which this happens, resulting in more mutations in the most important parts of our genomes.

 

Núria López-Bigas: "We look for cancer driver genes in tumours from patients"

In the video "Looking for a needle in a haystack", ICREA researcher at IRB Barcelona describes her work at the front of the Biomedical Genomics laboratory.

The group’s interests range from deciphering the basic biology of cancer to the development of useful tools for the diagnosis and personalised treatment of patients.

IRB Barcelona opens brand new laboratory for analysis of genomic 'big data'

Croatian scientist Fran Supek is launching his Genome Data Science (aGENDAS) laboratory.

aGENDAS is starting this April and will promote the research in Big Data, an strategic area also for the Barcelona Institute of Science and Technology (BIST).

With this new group, the Institute now hosts 24 laboratories and seven core facilities.

IRB Barcelona intensifies its research on cancer with two new recruits

As of November, Núria López-Bigas, winner of the 2016 Banco Sabadell Foundation Prize for Biomedical Research, will join IRB Barcelona to continue her research on cancer using computational biology.

The Institute has also recruited Croatian scientist Fran Supek, who will launch his laboratory in 2017.

Our research is focused on the study of cancer from a genomics perspective. We are particularly interested in the identification of cancer driver mutations, genes and pathways across tumour types and in the study of their potential as therapeutic targets.